Share-based Payment Arrangement, Expense of Skye Bioscience, Inc. from 31 Mar 2014 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Skye Bioscience, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2014 to 30 Sep 2025.
  • Skye Bioscience, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,914,136, a 0.39% decline year-over-year.
  • Skye Bioscience, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $8,238,369, a 21% increase year-over-year.
  • Skye Bioscience, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $8,317,480, a 742% increase from 2023.
  • Skye Bioscience, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $987,510, a 62% increase from 2022.
  • Skye Bioscience, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $608,199, a 30% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Skye Bioscience, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $8,238,369 $1,914,136 -$7,481 -0.39% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $8,245,850 $2,033,109 +$204,640 +11% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $8,041,210 $2,201,909 -$276,270 -11% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $8,317,480 $2,089,215 +$1,496,362 +252% 01 Oct 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
Q3 2024 $6,821,118 $1,921,617 +$1,761,410 +1099% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $5,059,708 $1,828,469 +$1,725,598 +1677% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $3,334,110 $2,478,179 +$2,346,600 +1783% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $987,510 $592,853 +$410,500 +225% 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
Q3 2023 $577,010 $160,207 +$16,083 +11% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $560,927 $102,871 -$41,493 -29% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2024 2024 Q2
Q1 2023 $602,420 $131,579 -$5,779 -4.2% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024 2024 Q1
Q4 2022 $608,199 $182,353 +$60,399 +50% 01 Oct 2022 31 Dec 2022 10-K 22 Mar 2024 2023 FY
Q3 2022 $547,800 $144,124 -$344,849 -71% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $892,649 $144,364 +$32,665 +29% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $859,984 $137,358 -$9,222 -6.3% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q4 2021 $869,206 $121,954 +$60,428 +98% 01 Oct 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
Q3 2021 $808,778 $488,973 +$340,608 +230% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $468,170 $111,699 +$82,990 +289% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $385,180 $146,580 +$82,438 +129% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q4 2020 $302,742 $61,526 01 Oct 2020 31 Dec 2020 10-K 28 Mar 2022 2021 FY
Q3 2020 $148,365 -$21,741 -13% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $28,709 01 Apr 2020 30 Jun 2020 10-Q 06 Aug 2021 2021 Q2
Q1 2020 $64,142 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021 2021 Q1
Q3 2019 $170,106 01 Jul 2019 30 Sep 2019 10-Q 06 Nov 2020 2020 Q3
Q3 2017 $181,608 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2017 2017 Q3
Q2 2017 $181,608 01 Apr 2017 30 Jun 2017 10-Q 11 Aug 2017 2017 Q2
Q1 2017 $152,169 -$29,439 -16% 01 Jan 2017 31 Mar 2017 10-Q 12 May 2017 2017 Q1
Q1 2016 $181,608 +$44,960 +33% 01 Jan 2016 31 Mar 2016 10-Q 12 May 2017 2017 Q1
Q3 2015 $4,286 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2016 2016 Q3
Q2 2015 $123,351 01 Apr 2015 30 Jun 2015 10-Q 12 Aug 2016 2016 Q2
Q1 2015 $136,648 +$136,648 01 Jan 2015 31 Mar 2015 10-Q 13 May 2015 2015 Q1
Q1 2014 $0 01 Jan 2014 31 Mar 2014 10-Q 13 May 2015 2015 Q1

Skye Bioscience, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $8,317,480 +$7,329,970 +742% 01 Jan 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
2023 $987,510 +$379,311 +62% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
2022 $608,199 -$261,007 -30% 01 Jan 2022 31 Dec 2022 10-K 22 Mar 2024 2023 FY
2021 $869,206 +$566,464 +187% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
2020 $302,742 01 Jan 2020 31 Dec 2020 10-K 28 Mar 2022 2021 FY
2014 $10,771 01 Jan 2014 31 Dec 2014 10-K 21 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.